Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Clover Bio’s COVID Vaccine Effective as Booster Against Omicron Variants

publication date: Jul 1, 2022

Shanghai Clover Biopharma reported its COVID vaccine produced a 19-fold increase in neutralizing antibody levels against the Omicron variant when used as a third-shot booster. Clover used its Trimer-Tag™ platform to develop SCB-2019, a stabilized trimeric form of the S-protein that is based on the original strain of the SARS-CoV-2 virus. It combined the antigen with Dynavax’s CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Clover expects the vaccine will prove to be an effective universal booster for all vaccines. More details....

Stock Symbol: (HK: 02197)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022